
Loading, please wait...

Loading, please wait...

This meta-analysis of 13 studies found no significant difference in in-hospital or 30-day mortality between cancer and non-cancer patients undergoing transcatheter aortic valve replacement (TAVR). However, 1-year and 2-year mortality were significantly higher in cancer patients. No differences were observed in major complications. TAVR is a viable option for cancer patients with severe aortic stenosis, but long-term prognosis is poorer.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This meta-analysis of 13 studies found no significant difference in in-hospital or 30-day mortality between cancer and non-cancer patients undergoing transcatheter aortic valve replacement (TAVR). However, 1-year and 2-year mortality were significantly higher in cancer patients. No differences were observed in major complications. TAVR is a viable option for cancer patients with severe aortic stenosis, but long-term prognosis is poorer.
5 months ago

Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today

A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday